Related Experiment Videos
Traumatic hemoptysis treated with recombinant human factor VIIa
James V O'Connor1, Deborah M Stein, Richard P Dutton
1Department of Thoracic and Vascular Surgery, R. Adams Cowley Shock Trauma Center, Baltimore, Maryland 21201, USA. joconnor@umm.edu
The Annals of Thoracic Surgery
|March 28, 2006
Summary
Massive hemoptysis from chest trauma is rare. Recombinant factor VIIa successfully treated life-threatening bleeding in a patient with blunt thoracic injury and coagulopathy.
Area of Science:
- Trauma surgery
- Hematology
- Critical care medicine
Background:
- Massive hemoptysis following blunt thoracic trauma is a rare but life-threatening condition.
- Recombinant factor VIIa is a hemostatic agent with established indications, but its use in traumatic hemoptysis is not documented.
Observation:
- A patient presented with massive hemoptysis after blunt force thoracic injury.
- The patient also exhibited traumatic coagulopathy, complicating bleeding management.
Findings:
- The case report details the successful administration of recombinant factor VIIa.
- This intervention effectively controlled the life-threatening hemoptysis in the context of chest trauma and coagulopathy.
Implications:
- Recombinant factor VIIa may be a viable treatment option for severe hemoptysis in blunt thoracic trauma patients.
- This finding expands the potential applications of recombinant factor VIIa in critical care settings.
- Further research is warranted to confirm the efficacy and safety of factor VIIa in this specific clinical scenario.